Merit Medical Systems
MMSI
Market cap $5.49B

92.97 USD

-0.61

0.65%

At close Jun 13, 4:00 PM EDT

After hours

92.97

+0.00

0.00%

1 day

-0.65%

5 days

-2.47%

1 month

-4.75%

3 months

-4.80%

6 months

-9.53%

Year to date

-3.23%

1 year

12.38%

5 years

113.48%

10 years

349.56%

About: Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.

Employees: 7,400

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

4,311% more call options, than puts

Call options by funds: $92.8M | Put options by funds: $2.1M

12% more capital invested

Capital invested by funds: $5.9B [Q4 2024] → $6.59B (+$688M) [Q1 2025]

1.28% more ownership

Funds ownership: 104.69% [Q4 2024] → 105.97% (+1.28%) [Q1 2025]

4% more repeat investments, than reductions

Existing positions increased: 139 | Existing positions reduced: 134

0% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]

2% less first-time investments, than exits

New positions opened: 50 | Existing positions closed: 51

3% less funds holding

Funds holding: 381 [Q4 2024] → 371 (-10) [Q1 2025]

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$103

11%

upside

Avg. target

$110

18%

upside

High target

$120

29%

upside

8 analyst ratings

8 positive

100%

0 neutral

0%

0 negative

0%

Piper Sandler Jason Bednar	18%upside $110	Overweight Maintained	23 May 2025
Canaccord Genuity Jon Young	20%upside $112	Buy Maintained	21 May 2025
Wells Fargo Larry Biegelsen	16%upside $108	Overweight Maintained	21 May 2025
Needham Mike Matson	16%upside $108	Buy Reiterated	20 May 2025
Raymond James Jayson Bedford	16%upside $108	Outperform Maintained	25 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about MMSI published over the past 30 days

The Market Is Vulnerable. 6 ‘Defensive' Stocks to Buy Now.

Stocks that aren't sensitive to economic ups and downs are a smart way to protect your portfolio.

The Market Is Vulnerable. 6 ‘Defensive' Stocks to Buy Now.

Zacks Investment Research

ALGN vs. MMSI: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Align Technology (ALGN) and Merit Medical (MMSI). But which of these two stocks is more attractive to value investors?

ALGN vs. MMSI: Which Stock Should Value Investors Buy Now?

Zacks Investment Research

MMSI Stock Gains Following Latest Merger to Boost Hemostasis Portfolio

Merit Medical aims to provide an additional effective solution that complements a wide range of percutaneous procedures, including interventional radiology and cardiology.

MMSI Stock Gains Following Latest Merger to Boost Hemostasis Portfolio

Merit Medical Acquires Biolife Delaware, L.L.C.

SOUTH JORDAN, Utah, May 20, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that it has acquired Biolife Delaware, L.L.C. (“Biolife”) in a merger transaction through which Biolife has become a wholly-owned subsidiary of Merit. Biolife, which is headquartered in Sarasota, Florida, manufactures unique patented hemostatic devices under the brand names StatSeal and WoundSeal.

Merit Medical Acquires Biolife Delaware, L.L.C.

Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis

SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis (CIE) received regulatory approval from Health Canada. With this approval, Merit intends to begin immediate commercialization of the device throughout Canada with devices shipped from Merit's Toronto distribution center.

Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis

Zacks Investment Research

LH vs. MMSI: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Labcorp (LH) and Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now?

LH vs. MMSI: Which Stock Is the Better Value Option?

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial

In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months.

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial

Zacks Investment Research

MMSI Stock Declines Despite Q1 Earnings Beating Estimates, Margins Up

Merit Medical benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter of 2025.

MMSI Stock Declines Despite Q1 Earnings Beating Estimates, Margins Up

Merit Medical Systems, Inc. (MMSI) Q1 2025 Earnings Call Transcript

Merit Medical Systems, Inc. (NASDAQ:MMSI ) Q1 2025 Results Conference Call April 24, 2025 5:00 PM ET Company Participants Fred Lampropoulos - Founder, Chairman & Chief Executive Officer Raul Parra - Chief Financial Officer and Treasurer Brian Lloyd - Chief Legal Officer & Corporate Secretary Conference Call Participants Jason Bednar - Piper Sandler Steve Lichtman - Oppenheimer Robbie Marcus - J.P. Morgan Craig Bijou - Bank of America Securities David Rescott - Baird Michael Petusky - Barrington Research Jim Sidoti - Sidoti & Company Jon Young - Canaccord Mike Matson - Needham Jayson Bedford - Raymond James Operator Welcome to the Merit Medical Systems First Quarter 2025 Earnings Conference Call.

Merit Medical Systems, Inc. (MMSI) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Compared to Estimates, Merit Medical (MMSI) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for Merit Medical (MMSI) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Merit Medical (MMSI) Q1 Earnings: A Look at Key Metrics

See News Rankings

Charts implemented using Lightweight Charts™